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Abstract
Background: Escherichia coli (E. coli) comprise part of the normal vaginal microflora. Transfer from mother to
neonate can occur during delivery resulting, sometimes, in neonatal bacterial disease. Here, we aim to report the
first outbreak of CTX-M ESBL-producing E. coli with evidence of mother-to-neonate transmission in an Irish neonatal
intensive care unit (NICU) followed by patient-to-patient transmission.
Methods: Investigation including molecular typing was conducted. Infection was defined by clinical and laboratory
criteria and requirement for antimicrobial therapy with or without positive blood cultures. Colonisation was
determined by isolation without relevant symptoms or indicators of infection.
Results: Index case was an 8-day-old baby born at 34 weeks gestation who developed ESBL-producing E. coli
infections at multiple body sites. Screening confirmed their mother as colonised with ESBL-producing E. coli. Five
other neonates, in the NICU simultaneously with the index case, also tested positive. Of these, four were colonised
while one neonate developed sepsis, requiring antimicrobial therapy. The second infected neonate’s mother was
also colonised by ESBL-producing E. coli. Isolates from all eight positive patients (6 neonates, 2 mothers) were
compared using pulsed-field gel electrophoresis (PFGE). Two distinct ESBL-producing strains were implicated, with
evidence of transmission between mothers and neonates for both strains. All isolates were confirmed as CTX-M
ESBL-producers. There were no deaths associated with the outbreak.
Conclusions: Resources were directed towards control interventions focused on hand hygiene and antimicrobial
stewardship, which ultimately proved successful. Since this incident, all neonates admitted to the NICU have been
screened for ESBL-producers and expectant mothers are screened at their first antenatal appointment. To date,
there have been no further outbreaks.
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Background
Escherichia coli (E. coli) comprise part of the normal vagi-
nal microflora. Vertical transfer from mother-to-neonate
can occur during delivery [1, 2] resulting, sometimes,
in severe neonatal bacterial disease [3]. Extended-
spectrum beta-lactamases (ESBLs) are plasmid-borne
beta-lactamases (such as TEM-, SHV-, OXA- and CTX-M
types) capable of hydrolysing and inactivating beta-lactam
antimicrobials with an oxyimino side chain, e.g., cephalo-
sporins (cefotaxime, ceftriaxone, ceftazidime) and the
oxyimino-monobactam (aztreonam) [4]. First reported in
1989, CTX-M enzymes have represented the most preva-
lent ESBL-type worldwide since 2000 [5, 6]. In 2013, it
was reported that incidence of community-associated in-
fections caused by CTX-M ESBL-producing bacteria,
particularly urinary tract infections in women of child-
bearing age, is increasing [7]. ESBL-producing E. coli have
been reported as a cause of neonatal sepsis and meningitis
[8] and mother-to-neonate transmission of ESBL pro-
ducers has been previously described [9]. The gastrointes-
tinal tract of infected or colonised patients, of all age
groups, is the most frequently-reported reservoir of ESBL-
producing organisms, and studies have shown that transi-
ent carriage of ESBL-producing organisms on the hands
of healthcare workers [10] or on artificial nails [11] may
also facilitate transmission.
Neonatal intensive care units (NICUs) have been de-
scribed as an interface between the hospital and the com-
munity due to the possibility of parents, while providing
daily care for their infants, introducing community-
associated multi-drug resistant organisms (MDROs) in-
cluding ESBL-producers [12, 13]. NICU stays have
become prolonged due to advances in modern medicine,
with duration of hospitalisation inversely related to gesta-
tional age and with increased risk of hospital-acquired in-
fection [14]. Specifically, risk factors associated with
colonisation or infection by ESBL-producers in NICUs in-
clude low gestational age, an immature immune system,
low birth weight, care in incubators, exposure to third-
generation cephalosporins [15, 16] and contaminated
breastmilk [17]. Septicaemia due to ESBL-producing or-
ganisms has been associated with a significantly increased
mortality rate compared to non-ESBL-producing isolates
[18]. In general, chemotherapeutic options for dealing
with ESBL-related infections are limited, and that
challenge is compounded by restrictive prescribing for
neonates due to the potential for adverse side-effects.
Therefore, when they occur, NICU-associated nosocomial
infections increase hospital costs substantially, with the
potential to prolong hospitalisation considerably, and are
responsible for 50% of deaths that occur beyond two
weeks of age [19]. In addition, there may be disruption of
healthcare services due to stringent infection control mea-
sures such as restriction of admissions or ward closures.
In this report, we describe the occurrence and out-
comes of the first ESBL-producing E. coli outbreak in an
Irish NICU. In particular, we detail the infection preven-
tion and control interventions that successfully brought
the outbreak to an end.
Methods
Setting
The University Maternity Hospital Limerick in Ireland
(UMHL) is a tertiary referral centre and includes a NICU
with a total of 19 cots. The catchment population of
UMHL is approximately 400,000. In the twelve months
prior to the outbreak, there were 4905 live births and 909
NICU admissions (of all gestational ages). At the time of
this outbreak, the NICU had one intensive care ward con-
sisting of four neonatal intensive care cots, five high de-
pendency cots and two isolation rooms. Two intermediate
care rooms, separated from the intensive care ward, con-
tained a further 10 cots. With respect to prevention of
nosocomial infection, the NICU intensive care ward pro-
vided four washing stations, alcohol hand gels at each bed-
space, and a nurse to patient ratio of 1:1 for ICU category
cots and 1:2 or 1:3 (depending on staffing levels) for the
remainder. A weekly multi-disciplinary NICU ward-round
was performed.
Index case identification
The index case for this outbreak was an infant born
(at 34 weeks gestation) in week 11 2013 via spontaneous
vaginal delivery. Whilst in the NICU swab cultures from
separate areas on the body were positive for ESBL-
producing E. coli resistant to co-amoxiclav, ceftriaxone,
aztreonam, ciprofloxacin, gentamicin and piperacillin/
tazobactam; sensitive to chloramphenicol, amikacin and
meropenem. The infant was placed in an isolation room
with contact precautions, chloramphenicol eye drops and
IV meropenem (dosed as per weight) administered for
seven days. They was discharged home on day 17 after
birth without need for further antimicrobials.
Infection control interventions
Contact tracing of all inpatients who may have been in
contact with the index case while in NICU was con-
ducted using urine samples and/or rectal swabs, one
sample for each neonate or mother was analysed de-
pending on what was most easily obtained. With con-
sent, the mother of the index case and mothers of
subsequently positive neonates were screened for the
presence of ESBLs using rectal swabs, high vaginal swabs
and mid-stream urine samples. Following a review of re-
lated literature, and to be prudent, a decision was made
to close the NICU to new admissions from week 12
2013, with exception of emergencies, and visiting was
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restricted to parents of inpatients only awaiting the re-
sults of contact tracing.
Following confirmatory cultures results, all infected or
colonised neonates were barrier nursed by personnel
wearing disposable gowns and gloves. In addition, a re-
striction was placed on the prescription of third gener-
ation cephalosporins. Due to the availability of only two
isolation rooms in the NICU, the index case and one
other neonate infected by ESBL-producers were isolated.
The remaining colonised neonates were cohorted in
incubators in the main NICU ward, with dedicated
single-patient equipment. Given physical environmental
constraints, it was not possible to increase the space be-
tween cots. Neonates who were fit for discharge were
cohorted to a single post-natal maternity ward to min-
imise cross-transmission.
The isolation of an ESBL-producing E. coli from a
NICU inpatient triggered initiation of the hospital’s out-
break management protocol, which involved meeting
with all key stakeholders, including executive manage-
ment, nursing administration, infection prevention and
control, consultant microbiologists, laboratory managers,
bed management, hygiene services, communications team
and NICU clinical director. Following a review of related
literature, and to be prudent, a decision was made to close
the NICU to new admissions, with exception of emergen-
cies, and visiting was restricted to parents of inpatients
only. Information leaflets regarding outbreak risks and
management were distributed to visiting parents. Appro-
priate public communication and a press statement were
issued by the Clinical Director. Arrangements were made
for antenatal inpatients whose neonates might require
NICU admission to be referred to other maternity hospi-
tals in Ireland. Empiric IV meropenem (dosed as per
weight) was administered for any infant demonstrating
signs of sepsis, pending microbiology analysis of urine or
rectal swabs. All infected or colonised neonates were
barrier nursed by personnel wearing disposable gowns
and gloves. In addition, a restriction was placed on
the prescription of third generation cephalosporins
With respect to hygiene, enhanced cleaning of the
NICU was instigated in parallel with increased auditing.
This involved twice-daily cleaning of affected areas and in-
cubators with detergent. Air sampling and environmental
sampling were not performed. An intensive targeted edu-
cational programme focussed on standard precautions,
particularly hand hygiene compliance and on modes of
transmission of ESBL-producing E. coli transmission was
provided to all clinical and administrative staff. Screening
of staff for carriage of ESBL-producing E. coli was not
conducted but instead it was considered of important to
put emphasis on zero tolerance to poor compliance with
the World Health Organisation’s “5 moments for hand hy-
giene”. Hand hygiene audits were performed with greater
frequency in affected areas, which involved twice weekly
observational audits at ward level. The last positive isolate
was identified in week 13 2013. The NICU re-opened later
in week 13 2013 and weekly multi-disciplinary meetings
were held until week 18 2013 to discuss and implement
hygiene recommendations, at which point the outbreak
was declared over. The last known neonate involved in
the outbreak was discharged in week 16 2013.
Microbiological and molecular detection of ESBL-producing
E. coli
At the time of the outbreak, the routine ESBL screening
policy targeted weekly screening of high-risk neonates
identified as such by their managing Consultant Neona-
tologists (but broadly categorised as premature or in
NICU for other than short term stay) and their mothers.
Screening specimens were cultured using ChromID™
ESBL agar (bioMérieux, Marcy l’ toile, France) and in-
cubated at 37 °C aerobically for 18–24 h. The colour
code guide provided by the manufacturer was followed for
review of any colonies identified; pink/brown = presump-
tive E. coli, green/blue = presumptive Klebsiella species,
white = other Enterobacteriaceae. All colonies were identi-
fied using MALDI-ToF MS (Bruker Daltonics, Bremen,
Germany) as described previously [20]. Confirmatory
testing was performed by disk diffusion on all organisms
that warranted further investigation (Thermo Scientific™
Oxoid™ Disks) using a disc dispenser; cefoxitin 30 μg
(FOX), cefapime 30 μg (FED), ceftazidime 30 μg (CAZ) &
ceftazidime-clavulanic acid 30/10 μg (CAZCV), cefotax-
ime 30 μg (CTX) & cefotaxime-clavulanic acid 30/10 μg
(CTXCV), Muller Hinton agar, 0.5 McFarland inoculum;
35 +/−2 °C, ambient air, 16–28 h. Following incubation,
the zone sizes of the cephalosporin disc to that of a ceph-
alosporin plus clavulanic acid combination disc were com-
pared to determine ESBL status. Criteria for positive ESBL
disc confirmatory testing on Enterobacteriaceae: a ≥5 mm
increase in zone diameter for either antimicrobial agent
tested in combination with clavulanic acid versus its zone
when tested alone. Criteria for negative ESBL disc
confirmatory testing on Enterobacteriaceae: zone sizes for
both cephalosporin and cephalosporin in combination
with clavulanic acid that is equal or show no greater differ-
ence in diameter than +/− 2 mm. Criterion for inconclu-
sive ESBL disc confirmatory testing: difference between
matched discs was >2 but <5 mm. In 2013, our protocols
dictated that any inconclusive disk diffusion result, would
warrant further confirmatory testing via Etest (bioMér-
ieux, Marcy l’ toile, France). No isolate from this out-
break required further testing via Etest.
The genetic relationships between the ESBL-producing
E. coli isolates were determined by pulsed-field gel elec-
trophoresis (PFGE) of XbaI-digested genomic DNA at
the Antimicrobial Resistance and Healthcare Associated
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Infections (AMRHAI) Reference Unit, Public Health
England, London, UK. Electrophoresis was performed
on a Bio-Rad CHEF DRII apparatus at 6 V cm−1 for 30 h
at 12 °C with ramping times of 5 s to 35 s. CTX-M sub-
typing was possible on all but one of the isolates subse-
quent to the outbreak.
Processing of breast milk specimens
Routine breast milk testing involved incubating undiluted
samples spread on blood agar (5-10% CO2) for up to 48 h,
blood agar with metronidazole for up to 48 h anaerobic-
ally, and MacConkey Agar for up to 48 h aerobically.
Results
Epidemiological features of the outbreak
Following detection of the index case (neonate two,
Table 1), between weeks 12 and 13 2013, following a
comprehensive screening seven additional screens of
two NICU mothers and five neonates proved positive
(Table 1). During this outbreak, infection was defined by
clinical and laboratory criteria and requirement for anti-
microbial therapy, while colonisation was defined by the
absence of relevant symptoms. In total, during the out-
break, 86 ESBL screens from 42 individuals were per-
formed. Of these, specimens from six neonates were
positive for ESBL-producing E. coli: two represented in-
fection and four represented colonisation. The mean
gestational age was 33 weeks (range 28 to 36 weeks).
There were no bacteraemias due to ESBL-producers.
The index case neonate’s mother was informed and
agreed to participate in screening. A rectal swab, a mid-
stream urine and a sample of expressed breast milk all
tested positive for ESBL-producing E. coli, as shown in
Table 2, with the same antibiogram as the isolate from
her neonate (detailed earlier). A high vaginal swab was
negative for the bacterium. This isolation of an ESBL-
producing E. coli was the first such result for the patient
who had never before had a culture-positive urine test.
One further neonate (neonate six, Table 1) who was in
the NICU at the time of the outbreak (Fig. 1) developed
urosepsis, eight days after the first detection of an ESBL-
producer in the NICU. While two blood specimens
proved negative, ESBL-producing E. coli were confirmed
from a urine sample and from a rectal swab. An identical
antibiogram to that of the index case neonate was noted.
The baby was treated with IV meropenem (dosed as per
weight). This neonate’s mother was screened whereupon a
high vaginal swab and a sample of expressed breast milk
cultured negative, but a rectal swab and a mid-stream
urine sample were positive for ESBL-producing E. coli
demonstrating the same antibiogram as previously found.
Again, this second mother had no previous documented
urinary tract infections and had never before had a
culture-positive urine test.
Of the remaining four neonates, all were clinically
stable, underwent weekly surveillance rectal cultures until
discharged from the NICU, and did not require treatment
with antimicrobials. All mothers of colonised infants
underwent screening to determine colonisation or infec-
tion and were found to be negative for ESBL-producers.
Molecular characteristics and antibiogram of the outbreak
All ESBL isolates identified during this outbreak had
an identical antibiogram regardless of culture source:
resistant to ampicillin/amoxicillin, co-amoxiclav, cef-
triazone, aztreonam, ciprofloxacin, gentamicin, cefurox-
ime, piperacillin/tazobactam, tri/sulfamethoxazole, while
susceptible to amikacin, chloramphenicol, ertapenem, and
meropenem. Following sequencing, all were found to bear
CTX-M-15 and OXA-1.
Following PFGE analysis (see Fig. 2), strain designated
LIME04ES-3 was found to be shared between the index
Table 1 Clinical characteristics of the neonates affected
Neonate Gestational
age at birth
(weeks)
Deliverya ESBL Source ESBL
resistance
mechanism
Days in NICU
prior to positive
result
Infected/
colonised
Feedingb Status at time
of discharge
from NICU
Repeat ESBL
testing post
outbreak
1 28 + 2 CS Rectal Unknown 46 Colonised EBM Alive Not performed
2 (index case) 34 + 5 VD Right buttock,
right eye, urine,
rectal
CTX-M 8 Infectedc EBM Alive Not performed
3 36 + 3 CS Rectal CTX-M 8 Colonised EBM Alive Not performed
4 36 + 3 CS Rectal CTX-M 8 Colonised EBM Alive Not performed
5 35 + 4 CS Rectal CTX-M 7 Colonised Formula Alive Not performed
6 30 + 6 VD Rectal, urine CTX-M 6 Infectedd EBM Alive ESBL positive rectal
swab September
2013
aCS: caesarean section, VD: vaginal delivery
bEBM: expressed breast milk
cOphthalmic, skin/soft tissue infection
dUrosepsis
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case, their mother and four other neonates, indicating
cross-transmission and was determined to be ST131. A
second strain (LIME04ES-4), determined to be ST1284,
was found in both the second infected neonate and their
mother.
Discussion
Mother-to-neonate transmission of ESBL-producing E.
coli in a European NICU has been described previously,
with a 2010 report from Switzerland of an outbreak that
began with transmission from a mother to her newborn
twins during vaginal delivery with subsequent spread fa-
cilitated by health care workers [21]. It is noteworthy
that a 2013 report traced another NICU outbreak to
ESBL-producers originating with a neonate born via cae-
sarean section and exclusively formula-fed [22]. Taken
together, these reports involving both delivery methods
exemplify the potential risk of infection and/or spread
regardless of mode of delivery [23].
The is first occurrence of an ESBL-producing E. coli
outbreak in a neonatal intensive care unit in Ireland me-
diated by mother-to-neonate transmission that has been
confirmed by molecular analysis. The index case’s
mother had a rectal swab and a mid-stream urine sam-
ple that cultured positive for ESBL-producing E. coli
although the organism was not detected from the high
vaginal swab. Consensus was that the likely route of
transmission was vertical from the mother’s colonised
perianal area during delivery. The second ESBL strain
(LIM04ES-4), from a separate neonate (neonate six) and
their mother, was again thought to have been transmit-
ted in the same manner from mother to child, who had
positive results from a rectal swab and mid-stream
urine.
Neither staff nor environmental screening were per-
formed at the time of the outbreak. The focus was in-
stead directed towards coordinating and managing the
NICU closure, staff education regarding hand hygiene &
transmissibility of ESBL-producers, antimicrobial stew-
ardship for NICU prescribers, and audit of hand & en-
vironmental hygiene. In contrast, a Greek outbreak of
SHV-5-producing Klebsiella pneumoniae in 2012, in-
volving 13 infected and three colonised neonates [24],
employed staff and environmental screening whereby
both staff and environmental sites were found to be
negative with no specific case identified as being the ori-
gin of the outbreak. They further implemented the same
outbreak management steps as were followed in our out-
break, with the exception of NICU closure. Without data
regarding environmental or staff screening, we believed
that the unit closure was key to reducing the duration of
the outbreak in allowing deep cleaning to occur, redu-
cing incubator/cot occupancy, lowering the nurse:infant
ratio, reducing the throughput of clinical staff into the
NICU and curtailing the number of antimicrobials in
use. Additional sequential control measures added value
to our outbreak control including cohort nursing and a
‘look back’ to identify the outbreak boundaries, as well
as determining recommendations for adherence regard-
ing: shared use of communal breast pumps; separation
of clean and used equipment; physical environment
cleaning; sufficient staffing with hygiene service and
cleaning personnel; and ensuring of sufficient supply of
sanitiser-filled alcohol hand dispensers.
Table 2 Microbiology culture results of mothers involved
High vaginal swab Rectal swab Mid-stream urine Expressed breast milk ESBL resistance mechanism
Mother of neonate 1 negative negative negative negative not tested
Mother of neonate 2 (index case) negative ESBL positive ESBL positive ESBL positive CTX-M
Mother of neonates 3&4 negative not tested not tested not tested not tested
Mother of neonate 5 negative negative negative not tested not tested
Mother of neonate 6 negative ESBL positive ESBL positive negative CTX-M
Fig. 1 Visual depiction of the timelines associated with this occurrence
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In the USA, active surveillance strategies have been
adopted by many NICUs to detect infants colonized with
antibiotic-resistant organisms albeit that the yield, risks,
benefits and costs of different strategies have not been
fully evaluated [25]. It is estimated that 21% of UK
NICUs undertake routine faecal/rectal swabbing for
ESBL-producing Enterobacteriaceae [26], but there is
currently no consensus in Europe with regard to screen-
ing in NICUs [27]. Irish data regarding screening remain
unknown and a study that reviewed the practices of
NICUs from both the UK and Ireland concluded that
NICUs “currently lack systematic neonatal infection sur-
veillance” [28, 29]. A 2014 Swedish study reported that
adopting once-a-week screening of all neonates can re-
duce time from admission to detection by eight days and
lead to a substantial reduction in secondary cases and
clinical infections [30]. Researchers in the USA deter-
mined that the rate of colonization by antibiotic-resistant
bacteria was low, particularly in neonates <7 days old and
have recommended that future studies should examine
the safety of targeted surveillance strategies focused on
older infants [25]. As a result of the outbreak reported
here, and as part of our active surveillance programme, all
neonates admitted currently to our NICU are screened for
ESBL-producers via culture of a urine sample or stool
sample or rectal swab on arrival. The screening culture
protocol is described in the methods section. Thereafter,
diagnostic microbiology analysis is performed if deemed
clinically necessary.
Similarly, there is also no consensus with regard to
ESBL screening of expectant mothers and, given the
mother-to-neonate transmission identified in this Irish
outbreak, this may be an area for enhanced surveillance
with a view to improvement in reduction of neonatal
risk. As a consequence of this outbreak, our current
practice (similar to an approach being adopted as pru-
dent in Norway [31]) is that all pregnant women pre-
senting at their first antenatal appointment have ESBL
screening performed via a urine sample, albeit resulting
perhaps in the screening of inappropriately large num-
bers of healthy young women with a recognised low
positive predictive value.
Conclusions
In our setting, which may be comparable to many others,
once an outbreak was declared, containment and control
were achieved via timely closure of the unit to new admis-
sions, staff education, strict adherence to hand hygiene
measures with frequent auditing of staff compliance,
cohorting infected neonates, screening of all inpatients,
enhanced deep cleaning of all equipment within the NICU
and utilising of an outbreak management team. We bene-
fited from modification of the antimicrobial policy to
move from broad-spectrum antibiotics to those that
the problematic strain was susceptible to. A multidiscip-
linary approach was employed incorporating frequent
communication with parents while visitor restrictions
were enforced. With a deficit in national or international
screening guidelines, in the context of a rising national
ESBL-producer prevalence in Ireland, our screening prac-
tices as described here continue. To date, we have not had
further ESBL outbreaks on any of our antenatal or postna-
tal wards due to appropriate early infection control man-
agement of newly identified ESBL patients. We hope that
others may learn from our experience of successfully man-
aging a neonatal ESBL outbreak.
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